Yuyu Pharma, Inc.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-02-28
- Employees
- 259
- Market Cap
- -
- Website
- http://www.yuyu.co.kr
Clinical Trials
7
Active:0
Completed:7
Trial Phases
3 Phases
Phase 1:3
Phase 2:2
Phase 3:2
Drug Approvals
1
PHILIPPINES:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (42.9%)Phase 2
2 (28.6%)Phase 3
2 (28.6%)Phase 2, Multi-center, Randomized, Double- Masked and Placebo-Controlled Study of YP-P10 Ophthalmic Solution Compared to Placebo in Subjects With Dry Eye (ICECAP 1)
Phase 2
Completed
- Conditions
- Dry Eye
- Interventions
- Drug: 0.3% YP-P10 Ophthalmic SolutionDrug: 1% YP-P10 Ophthalmic SolutionDrug: YP-P10 Placebo Ophthalmic Solution (vehicle)
- First Posted Date
- 2022-07-20
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Yuyu Pharma, Inc.
- Target Recruit Count
- 257
- Registration Number
- NCT05467293
- Locations
- 🇺🇸
Cornea Consultants of Arizona, Phoenix, Arizona, United States
🇺🇸Aesthetic Eye Care Institute, Newport Beach, California, United States
🇺🇸Vision Institute, Colorado Springs, Colorado, United States
Pharmacokinetics and Safety/Tolerability of YY-201 in Comparison to Dutasteride and Tadalafil
Phase 1
Completed
- Conditions
- Benign Prostatic Hyperplasia
- Interventions
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2017-11-24
- Lead Sponsor
- Yuyu Pharma, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT03240939
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
A Study to Investigate the Pharmacokinetic Drug Interactions Between Dutasteride and Tadalafil in Healthy Male Subjects
- First Posted Date
- 2016-07-20
- Last Posted Date
- 2017-04-04
- Lead Sponsor
- Yuyu Pharma, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT02839122
Efficacy and Safety Study of Combination of Ginkgo Extract and Ginseng Extract in Children With ADHD(Attention Deficit Hyperactivity Disorder)
- First Posted Date
- 2012-02-20
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Yuyu Pharma, Inc.
- Target Recruit Count
- 144
- Registration Number
- NCT01536210
- Locations
- 🇰🇷
Hallym University Hospital, Anyang-si, Korea, Republic of
🇰🇷Inje University Ilsan Paik Hospital, Goyang-Si, Korea, Republic of
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
Pharmacokinetics of Maxmarvil® in Healthy Postmenopausal Women
Phase 1
Completed
- Conditions
- Osteoporosis
- Interventions
- Drug: Maxmarvil®
- First Posted Date
- 2012-02-03
- Last Posted Date
- 2019-02-25
- Lead Sponsor
- Yuyu Pharma, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01526278
- Locations
- 🇰🇷
Ajou University Hospital, Suwon, Korea, Republic of
- Prev
- 1
- 2
- Next
News
No news found